Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users

Conditions

• Healthy, Non-Drug- Dependent, Recreational Opioid Users

Eligibility Criteria

Sex

ALL

Age

18 Years - 55 Years

Healthy Volunteers

Accepted

Interventions

• Placebo — DRUG
  Placebo
• Oxycodone 20mg — DRUG
  oxycodone 20mg
• gabapentin 600 mg — DRUG
  Gabapentin 600 mg
• Gabapentin 1200mg — DRUG
  Gabapentin 1200mg
• Gabapentin 600 mg + Oxycodone 20 mg — DRUG
  Gabapentin 600 mg + Oxycodone 20 mg
• Gabapentin 1200 mg + Oxycodone 20 mg — DRUG
  Gabapentin 1200 mg + Oxycodone 20 mg

Study Details

The purpose of the present study is to assess prospectively the abuse potential of gabapentin when taken with and without oxycodone compared to placebo in healthy non-drug-dependent recreational opioid drug users under fasted condition.

Key Dates

First listed

Sep 10, 2026

Start date

Aug 3, 2026

Status verified

Sep 2026

Primary completion

Jan 31, 2027

Completion

Feb 14, 2027

Study Design

Enrollment

60 participants (estimated)

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Arms

• Placebo Comparator: Treatment Phase A
• Active Comparator: Treatment Phase B
• Active Comparator: Treatment Phase C
• Active Comparator: Treatment Phase D
• Active Comparator: Treatment Phase E
• Active Comparator: Treatment Phase F

Primary Outcome Measure

Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax) [ Time Frame: Up to 24 hours after treatments ]

Central Contacts

• Dik Ng
  (+44) 1304626895
  [email protected]

Locations (1)

Find similar trials in Overland Park, KS